Panagora Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Panagora Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,751	Closed	-$863K	–	1526
2023 Q1	$863K	Buy	4,751 +1,505	+46%	+$288K	0.01%	896
2022 Q4	$638K	Buy	3,246 +479	+17%	+$103K	﹤0.01%	1067
2022 Q3	$622K	Buy	+2,767	New	+$560K	﹤0.01%	1065
2020 Q4	–	Sell	-233	Closed	-$18K	–	2971
2020 Q3	$18K	Buy	+233	New	+$19.9K	﹤0.01%	2236

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Panagora Asset Management's KRTX Position: Q2 2023 in Review

Panagora Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 4,751 shares — an estimated $863K sold.

Panagora Asset Management first reported a position in KRTX in Q3 2020 and held it in 4 quarters. The position peaked at $863K in Q1 2023. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

Panagora Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Panagora Asset Management sold 4,751 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $863K.
Panagora Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
Panagora Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $863K in Q1 2023.
289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Panagora Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.